Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pharmacokinetics
Biotech
Arbutus ends COVID, RNA destabilizer plans over preclinical data
Arbutus has become the latest biotech to exit the COVID-19 space, instead tightening its focus on hepatitis B.
James Waldron
Sep 12, 2023 5:34am
Synexa buys Syrinx to capture growing bioanalysis market
May 23, 2022 3:05pm
Liminal stops plan to advance fibrosis drug after seeing PK data
Jun 1, 2021 8:50am
Provention's diabetes drug appears to have AdComm's support
May 25, 2021 3:13pm
Sygnature Discovery snaps up fellow British CRO XenoGesis
Sep 29, 2020 7:45am
Stanford's ultrafast insulin cuts peak time to efficacy in pigs
Jul 1, 2020 2:00pm
